BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration
RVMD•Collaboration terms
- BeOne Medicines and Revolution Medicines announce clinical development and regional commercialization collaboration
- BeOne Medicines receives exclusive rights to four Revolution Medicines assets in select Asian markets.
- BeOne Medicines will fund and conduct a global Phase 3 study for the RAS(ON) inhibitor.
- Revolution Medicines is eligible for milestone payments and tiered royalties in the partnered region.
